UI Hospitals and Clinics

Clinical Trial Details

Short Title
Octreotide with or without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors
Official Title

90Y-DOTA-tyr 3 Octreotide with or without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults: A Randomized, Placebo controlled Phase II Trial with Dosimetry Guided Dosing of 90Y -DOTA-tyr 3 Octreotide (60)

Description

Participants in this study have been diagnosed with neuroblastoma or a neuroendocrine tumor. The purpose of this research study is to assess the safety and effectiveness of the combination of retinoic acid and Onalta® in treating your neuroblastoma or neuroendocrine tumor. Approximately 60 people will take part in this study conducted by investigators at the University of Iowa. Study involvement is life long with treatment lasting approximately 18-24 weeks.

Start Date
June 1, 2009
End Date
November 13, 2013
Gender Preference
None
Age Group
0 - 99 years
Principal Investigator
M. Sue O'Dorisio, MD
Contact Info

M. Sue O'Dorisio, 319-356-7873

Department
Department or Field of Study
Keywords
cancer ; IRB#200904707 ; neuroblastoma ; neuroendocrine tumor ; o ; onalta® ; pediatric ; phase 2 ; phase II ; retinoic acid ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.